Amalgamated Bank Sells 2,085 Shares of Bruker Corporation $BRKR

Amalgamated Bank cut its stake in shares of Bruker Corporation (NASDAQ:BRKR) by 4.0% during the 2nd quarter, Holdings Channel reports. The fund owned 50,355 shares of the medical research company’s stock after selling 2,085 shares during the period. Amalgamated Bank’s holdings in Bruker were worth $2,075,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also bought and sold shares of BRKR. Sculptor Capital LP boosted its stake in Bruker by 51.6% during the first quarter. Sculptor Capital LP now owns 2,598,438 shares of the medical research company’s stock worth $108,459,000 after acquiring an additional 884,423 shares in the last quarter. Goldman Sachs Group Inc. boosted its stake in Bruker by 107.3% during the first quarter. Goldman Sachs Group Inc. now owns 1,465,319 shares of the medical research company’s stock worth $61,162,000 after acquiring an additional 758,301 shares in the last quarter. AQR Capital Management LLC boosted its stake in Bruker by 65.9% during the first quarter. AQR Capital Management LLC now owns 1,476,605 shares of the medical research company’s stock worth $60,688,000 after acquiring an additional 586,516 shares in the last quarter. Vaughan Nelson Investment Management L.P. boosted its stake in Bruker by 71.2% during the second quarter. Vaughan Nelson Investment Management L.P. now owns 1,293,645 shares of the medical research company’s stock worth $53,298,000 after acquiring an additional 537,845 shares in the last quarter. Finally, Nuveen LLC bought a new position in Bruker during the first quarter worth $20,764,000. 79.52% of the stock is owned by institutional investors.

Bruker Stock Down 0.4%

BRKR opened at $40.20 on Thursday. The company has a debt-to-equity ratio of 1.31, a current ratio of 1.61 and a quick ratio of 0.70. The company’s 50-day moving average is $34.78 and its 200 day moving average is $37.04. Bruker Corporation has a fifty-two week low of $28.53 and a fifty-two week high of $64.64. The firm has a market capitalization of $6.10 billion, a P/E ratio of 77.31, a PEG ratio of 5.31 and a beta of 1.26.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share for the quarter, beating analysts’ consensus estimates of $0.33 by $0.12. Bruker had a net margin of 2.31% and a return on equity of 17.89%. The company had revenue of $860.50 million for the quarter, compared to analyst estimates of $847.40 million. During the same period last year, the firm earned $0.60 earnings per share. The firm’s revenue was down .5% on a year-over-year basis. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. Research analysts expect that Bruker Corporation will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 2nd. Stockholders of record on Monday, December 8th will be paid a $0.05 dividend. The ex-dividend date is Monday, December 8th. This represents a $0.20 annualized dividend and a dividend yield of 0.5%. Bruker’s dividend payout ratio (DPR) is presently -125.00%.

Insider Buying and Selling at Bruker

In other news, Director Cynthia M. Friend sold 3,535 shares of the firm’s stock in a transaction that occurred on Friday, September 12th. The shares were sold at an average price of $32.25, for a total value of $114,003.75. Following the completion of the transaction, the director directly owned 18,016 shares in the company, valued at approximately $581,016. This trade represents a 16.40% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 27.30% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms have weighed in on BRKR. TD Cowen raised their price objective on shares of Bruker from $40.00 to $42.00 and gave the company a “hold” rating in a research note on Tuesday. Stifel Nicolaus set a $40.00 price objective on shares of Bruker and gave the company a “hold” rating in a research note on Tuesday, August 5th. Barclays raised their price objective on shares of Bruker from $40.00 to $45.00 and gave the company an “overweight” rating in a research note on Tuesday. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Bruker in a research note on Wednesday, October 8th. Finally, Wells Fargo & Company dropped their price objective on shares of Bruker from $50.00 to $48.00 and set an “overweight” rating on the stock in a research note on Wednesday. Five equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $48.30.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.